AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3294814 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylene blue (MB) 50 mg combined with dexamethasone 1 mg in single capsules
Number of subjects: 13
Study 12575849 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic plaque psoriasis patients (group I)
Number of subjects: 200
Study 12575849 — intervention group
Group type: COMPARATOR
Intervention: Other non-allergic skin complaints patients (group II)
Number of subjects: 200
Study 12575849 — intervention group
Group type: COMPARATOR
Intervention: Patients suspected of having allergic contact dermatitis (group III)
Number of subjects: 200
Study 12575849 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic plaque psoriasis patients with > or = 5 years old disease
Number of subjects: 200
Study 30016935 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 months of Dialectical Behaviour Therapy (DBT)
Number of subjects: 240
Study 30016935 — intervention group
Group type: COMPARATOR
Intervention: 12 months of Dialectical Behaviour Therapy (DBT)
Number of subjects: 240
Study 26903390 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Prednisolone
Number of subjects: 416
Study 26903390 — intervention group
Group type: COMPARATOR
Intervention: Oral Indomethacin
Number of subjects: 416
Study 24485847 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with bupropion (max 450 mg/d) and escitalopram (max 40 mg/d) for 12 weeks
Number of subjects: 245
Study 24485847 — intervention group
Group type: COMPARATOR
Intervention: Escitalopram monotherapy
Number of subjects: 245
Study 24485847 — intervention group
Group type: COMPARATOR
Intervention: Bupropion monotherapy
Number of subjects: 245
Study 22568663 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg immediate release (IR) oxycodone
Number of subjects: 19
Study 22568663 — intervention group
Group type: EXPERIMENTAL
Intervention: Crushed 40 mg controlled release (CR) oxycodone
Number of subjects: 19
Study 22568663 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg controlled release (CR) oxycodone
Number of subjects: 19
Study 22568663 — intervention group
Group type: COMPARATOR
Intervention: 40 mg controlled release (CR) oxycodone
Number of subjects: 19
Study 20138720 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose levocabastine nasal spray
Number of subjects: 335
Study 20138720 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose levocabastine nasal spray
Number of subjects: 335
Study 20138720 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 335
Study 18540482 — intervention group
Group type: EXPERIMENTAL
Intervention: Test product (Blastoferon)
Number of subjects: 36
Study 18540482 — intervention group
Group type: COMPARATOR
Intervention: Innovator product (Interferon beta la)
Number of subjects: 36
Study 18540482 — intervention group
Group type: EXPERIMENTAL
Intervention: Both products
Number of subjects: 36
Study 15780139 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural group intervention (8 weekly sessions of 2 hours each and a booster session)
Number of subjects: 0
Study 15780139 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study 15780139 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural group intervention
Number of subjects: 0
Study 12221168 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta1a (Rebif)
Number of subjects: 365
Study 12221168 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 365
Study 11783208 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus Traditional Chinese Medicine (TCM)
Number of subjects: 41
Study 11783208 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy plus Traditional Chinese Medicine (TCM)
Number of subjects: 41
Study 11783208 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 41
Study 11783208 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 41
Study 8538929 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 60 mg/day
Number of subjects: 8
Study 8538929 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 1768560 — intervention group
Group type: EXPERIMENTAL
Intervention: ICS 205-930 (0.15-0.18 mg kg-1, infused i.v.)
Number of subjects: 13
Study 1768560 — intervention group
Group type: COMPARATOR
Intervention: Placebo (infused i.v.)
Number of subjects: 13
Study 1768560 — intervention group
Group type: EXPERIMENTAL
Intervention: ICS 205-930
Number of subjects: 13
Study 1768560 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 6121527 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen
Number of subjects: 20
Study 6121527 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31012999 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal extract
Number of subjects: 77
Study 31012999 — intervention group
Group type: COMPARATOR
Intervention: 2.5% benzoyl peroxide
Number of subjects: 77
Study 29098254 — intervention group
Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser
Number of subjects: 60
Study 29098254 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic irrigation
Number of subjects: 60
Study 29098254 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 26122744 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance-based financing (PBF)
Number of subjects: 0
Study 26122744 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study 24461572 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral stimulation program for 15 min at least for 10 days before introduction of oral feeding
Number of subjects: 86
Study 24461572 — intervention group
Group type: COMPARATOR
Intervention: Control group (no oral stimulation)
Number of subjects: 86
Study 24461572 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral stimulation program
Number of subjects: 86
Study 22341836 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybutynin (5 mg twice daily)
Number of subjects: 50
Study 22341836 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 20336162 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide LAR (long-acting release)
Number of subjects: 0
Study 20336162 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17693960 — intervention group
Group type: COMPARATOR
Intervention: Diet C: day/night formulas administered in synchrony with the environment
Number of subjects: 30
Study 17693960 — intervention group
Group type: COMPARATOR
Intervention: Diet B: 06:00-18:00 normal initiation milk, 18:00-06:00 dissociated night formula
Number of subjects: 30
Study 16296426 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone treatment (HealOzone) applied once for 40 seconds to the test molar.
Number of subjects: 41
Study 16296426 — intervention group
Group type: COMPARATOR
Intervention: Untreated control lesions (contra‐lateral lesions).
Number of subjects: 41
Study 11235682 — intervention group
Group type: EXPERIMENTAL
Intervention: Full investigation group (mediastinoscopy and computed tomography of the chest)
Number of subjects: 634
Study 11235682 — intervention group
Group type: EXPERIMENTAL
Intervention: Full investigation group
Number of subjects: 634
Study 11235682 — intervention group
Group type: COMPARATOR
Intervention: Limited investigation group (bone scintigraphy and computed tomographic scanning of the head, liver, and adrenal glands)
Number of subjects: 634
Study 11235682 — intervention group
Group type: COMPARATOR
Intervention: Limited investigation group
Number of subjects: 634
Study 11235682 — intervention group
Group type: EXPERIMENTAL
Intervention: Full investigation strategy
Number of subjects: 634
Study 9512198 — intervention group
Group type: EXPERIMENTAL
Intervention: High fat diet (48% energy as fat)
Number of subjects: 39
Study 9512198 — intervention group
Group type: COMPARATOR
Intervention: Low fat diet (22.2% energy as fat)
Number of subjects: 39
Study 7999657 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-assisted epidural analgesia (fentanyl 10 mcg/mL and bupivacaine 1 mg/mL for the first 2 days)
Number of subjects: 62
Study 7999657 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-assisted epidural analgesia
Number of subjects: 62
Study 7999657 — intervention group
Group type: COMPARATOR
Intervention: Continuous epidural infusion
Number of subjects: 62
Study 3180725 — intervention group
Group type: EXPERIMENTAL
Intervention: Eight-week communications training program
Number of subjects: 0
Study 3180725 — intervention group
Group type: COMPARATOR
Intervention: Self-help meetings (Control)
Number of subjects: 0
Study 30299520 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal condition
Number of subjects: 140
Study 30299520 — intervention group
Group type: EXPERIMENTAL
Intervention: External condition
Number of subjects: 140
Study 30299520 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 140
Study 31299670 — intervention group
Group type: EXPERIMENTAL
Intervention: Likelihood-based multiple imputation strategy for imputing observations below the limit of detection (LOD) while accounting for differential batch assignment.
Number of subjects: 0
Study 31299670 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete-case analysis including batch indicator terms in the analysis model.
Number of subjects: 0
Study 27876528 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyhexamethylene biguanide (PHMB) preserved multipurpose care solution (MPS)
Number of subjects: 139
Study 27876528 — intervention group
Group type: COMPARATOR
Intervention: Peroxide-based solution system
Number of subjects: 139
Study 27876528 — intervention group
Group type: EXPERIMENTAL
Intervention: Solution-induced corneal staining (SICS)
Number of subjects: 139
Study 27876528 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with substantial bioburden on lenses or storage case
Number of subjects: 139
Study 25878904 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (transcranial direct current stimulation)
Number of subjects: 60
Study 25878904 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS (control)
Number of subjects: 60
Study 23588130 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored message addressing perceived barriers to HPV vaccination
Number of subjects: 94
Study 23588130 — intervention group
Group type: COMPARATOR
Intervention: Nontailored message about HPV vaccination
Number of subjects: 94
Study 20652715 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfascial nonabsorbable sutures
Number of subjects: 40
Study 20652715 — intervention group
Group type: COMPARATOR
Intervention: Metal tacks
Number of subjects: 40
Study 18847523 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine-lignocaine mixture (Cophenylcaine)
Number of subjects: 73
Study 18847523 — intervention group
Group type: COMPARATOR
Intervention: Xylometazoline (Otrivine)
Number of subjects: 73
Study 17342510 — intervention group
Group type: EXPERIMENTAL
Intervention: Autograft
Number of subjects: 24
Study 17342510 — intervention group
Group type: COMPARATOR
Intervention: Fusion cage
Number of subjects: 24
Study 15037937 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 0.2 percent nitroglycerin ointment
Number of subjects: 60
Study 15037937 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerin-free placebo
Number of subjects: 60
Study 11102592 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo vaginal ring (IVR-2)
Number of subjects: 166
Study 11102592 — intervention group
Group type: COMPARATOR
Intervention: Control (non-use of ring)
Number of subjects: 166
Study 8741469 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous epidural block instituted prior to induction of anesthesia and maintained throughout surgery (Group 1)
Number of subjects: 16
Study 8741469 — intervention group
Group type: COMPARATOR
Intervention: Continuous epidural block instituted upon peritoneal closure and maintained thereafter (Group 2)
Number of subjects: 16
Study 8741469 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Group 1 and Group 2)
Number of subjects: 16
Study 1397911 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon dioxide (CO2)
Number of subjects: 56
Study 1397911 — intervention group
Group type: COMPARATOR
Intervention: Air
Number of subjects: 56
Study 3894474 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine 5 mg
Number of subjects: 12
Study 3894474 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine 10 mg
Number of subjects: 12
Study 3894474 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine 20 mg
Number of subjects: 12
Study 30511879 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban (2.5 mg twice daily)
Number of subjects: 563
Study 30511879 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 563
Study 28347608 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine delivered as sprays (MAD group)
Number of subjects: 106
Study 28347608 — intervention group
Group type: COMPARATOR
Intervention: Intranasal dexmedetomidine delivered as drops (syringe group)
Number of subjects: 106
Study 26279172 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based virtual reality balance training (n=11)
Number of subjects: 23
Study 26279172 — intervention group
Group type: COMPARATOR
Intervention: Conventional home balance training (n=12)
Number of subjects: 23
Study 24823456 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 nights of 4 hours in bed
Number of subjects: 13
Study 24823456 — intervention group
Group type: COMPARATOR
Intervention: 2 nights of 10 hours in bed
Number of subjects: 13
Study 22995383 — intervention group
Group type: COMPARATOR
Intervention: Controls (alive patients without VT/VF)
Number of subjects: 33
Study 22995383 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients in the arrhythmia group (with VT/VF/death outcomes)
Number of subjects: 33
Study 22995383 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with VT/VF
Number of subjects: 33
Study 22995383 — intervention group
Group type: EXPERIMENTAL
Intervention: Decrease in QTVI after PVC
Number of subjects: 33
Study 19493173 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-guided group with process goals
Number of subjects: 48
Study 19493173 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-guided group with outcome goals
Number of subjects: 48
Study 19493173 — intervention group
Group type: EXPERIMENTAL
Intervention: Groups with process goals
Number of subjects: 48
Study 19493173 — intervention group
Group type: COMPARATOR
Intervention: Outcome goal participants
Number of subjects: 48
Study 17323429 — intervention group
Group type: EXPERIMENTAL
Intervention: Topography-guided customized aspheric treatment zone (CATz) ablation
Number of subjects: 54
Study 17323429 — intervention group
Group type: COMPARATOR
Intervention: Conventional ablation
Number of subjects: 54
Study 17323429 — intervention group
Group type: COMPARATOR
Intervention: Comparison between CATz and conventional ablation
Number of subjects: 54
Study 15310345 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of inhaled medical air and titrated intravenous midazolam
Number of subjects: 697
Study 15310345 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of inhaled 40% nitrous oxide in oxygen and titrated intravenous midazolam
Number of subjects: 697
Study 15310345 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of inhaled mixture of sevoflurane 0.3% and nitrous oxide 40% in oxygen with titrated intravenous midazolam
Number of subjects: 697
Study 12796591 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily schedule of topotecan (1.5 mg/m2 daily for 5 days every 3 weeks)
Number of subjects: 60
Study 12796591 — intervention group
Group type: COMPARATOR
Intervention: Continuous-infusion schedule of topotecan (1.3 mg/m2 per day over 72 hours every 4 weeks)
Number of subjects: 60
Study 10479878 — intervention group
Group type: EXPERIMENTAL
Intervention: Usnic acid and zinc sulphate compound (Zeta N, Bergamon Italia) administered intravaginally before and after RS (n = 25)
Number of subjects: 100
Study 10479878 — intervention group
Group type: EXPERIMENTAL
Intervention: Usnic acid and zinc sulphate compound (Zeta N, Bergamon Italia) administered intravaginally after RS (n = 25)
Number of subjects: 100
Study 10479878 — intervention group
Group type: COMPARATOR
Intervention: Control group (no therapy after RS) (n = 50)
Number of subjects: 100
Study 10479878 — intervention group
Group type: EXPERIMENTAL
Intervention: Usnic acid and zinc sulphate compound (Zeta N, Bergamon Italia) administered intravaginally (both before and after RS)
Number of subjects: 100
Study 8753634 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Discharge (ED) group (n = 319)
Number of subjects: 1317
Study 8753634 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent group (n = 456)
Number of subjects: 1317
Study 8753634 — intervention group
Group type: COMPARATOR
Intervention: Preprogram control group (n = 542)
Number of subjects: 1317
Study 8753634 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (ED, concurrent, preprogram control)
Number of subjects: 1317
Study 1888047 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine with 0.1 mEq sodium bicarbonate added to each 20 ml (n = 30)
Number of subjects: 60
Study 1888047 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine with 1:300,000 epinephrine (n = 30)
Number of subjects: 60
Study 1888047 — intervention group
Group type: COMPARATOR
Intervention: Control period prior to epidural catheter insertion
Number of subjects: 60
Study 7158401 — intervention group
Group type: EXPERIMENTAL
Intervention: iohexol
Number of subjects: 40
Study 7158401 — intervention group
Group type: EXPERIMENTAL
Intervention: ioxaglate
Number of subjects: 40
Study 7158401 — intervention group
Group type: COMPARATOR
Intervention: metrizamide
Number of subjects: 40
Study 4003494 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical indomethacin 1%
Number of subjects: 35
Study 4003494 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 30552264 — intervention group
Group type: EXPERIMENTAL
Intervention: Humanoid robot distraction during IVI
Number of subjects: 80
Study 30552264 — intervention group
Group type: COMPARATOR
Intervention: Standard care during IVI
Number of subjects: 80
Study 30552264 — intervention group
Group type: EXPERIMENTAL
Intervention: Humanoid robot distraction
Number of subjects: 80
Study 26037728 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactoferrin 250 mg capsules once daily for eight consecutive weeks
Number of subjects: 200
Study 26037728 — intervention group
Group type: COMPARATOR
Intervention: Ferrous sulphate 150 mg capsules once daily for eight consecutive weeks
Number of subjects: 200
Study 26037728 — intervention group
Group type: COMPARATOR
Intervention: Ferrous sulphate
Number of subjects: 200
Study 25078310 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab-based treatment (alemtuzumab followed by low-dose tacrolimus and mycophenolate without steroids)
Number of subjects: 852
Study 25078310 — intervention group
Group type: COMPARATOR
Intervention: Basiliximab-based treatment (basiliximab followed by standard-dose tacrolimus, mycophenolate, and prednisolone)
Number of subjects: 852
Study 25078310 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab-based treatment
Number of subjects: 852
Study 25078310 — intervention group
Group type: COMPARATOR
Intervention: Basiliximab-based treatment
Number of subjects: 852
Study 22177854 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometer-based program with socio-cognitive intervention
Number of subjects: 65
Study 22177854 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 65
Study 19933534 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemofiltration during CPB
Number of subjects: 185
Study 19933534 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative steroid therapy
Number of subjects: 185
Study 19933534 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 185
Study 18338980 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval aerobic training
Number of subjects: 40
Study 18338980 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity aerobic training
Number of subjects: 40
Study 18338980 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training
Number of subjects: 40
Study 18338980 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training (both high and moderate intensity)
Number of subjects: 40
Study 18338980 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training and moderate-intensity aerobic training
Number of subjects: 40
Study 16187727 — intervention group
Group type: EXPERIMENTAL
Intervention: Coralline hydroxyapatite (CH) backfill
Number of subjects: 12
Study 16187727 — intervention group
Group type: COMPARATOR
Intervention: No backfill
Number of subjects: 12
Study 12581014 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram treatment for 8 weeks
Number of subjects: 30
Study 12581014 — intervention group
Group type: COMPARATOR
Intervention: No therapy (Control)
Number of subjects: 30
Study 8863008 — intervention group
Group type: EXPERIMENTAL
Intervention: Nibbling diet (12 meals per day)
Number of subjects: 11
Study 8863008 — intervention group
Group type: EXPERIMENTAL
Intervention: Gorging diet (3 meals per day)
Number of subjects: 11
Study 1521954 — intervention group
Group type: EXPERIMENTAL
Intervention: Training at lactate threshold (at LT)
Number of subjects: 25
Study 1521954 — intervention group
Group type: EXPERIMENTAL
Intervention: Training above lactate threshold (greater than LT)
Number of subjects: 25
Study 1521954 — intervention group
Group type: COMPARATOR
Intervention: Sedentary control group
Number of subjects: 25
Study 6386485 — intervention group
Group type: EXPERIMENTAL
Intervention: Probucol
Number of subjects: 42
Study 6386485 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 6386485 — intervention group
Group type: COMPARATOR
Intervention: Colestipol
Number of subjects: 42
Study 6386485 — intervention group
Group type: COMPARATOR
Intervention: Probucol plus Colestipol
Number of subjects: 42
Study 30506623 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (3 formulations, each for two 1-week periods)
Number of subjects: 0
Study 29506183 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-rich diet
Number of subjects: 158
Study 29506183 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein-rich diet
Number of subjects: 158
Study 29506183 — intervention group
Group type: EXPERIMENTAL
Intervention: Monounsaturated fat-rich diet
Number of subjects: 158